Volume 22 Issue 5
May  2024
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2024  >  22(5): 768-771
ZHANG Ying, YANG Bo, YIN Tian, ZHAO Yue, ZHANG Xinyi, LI Ying. Application of intermittent cytoreductive surgery + hyperthermic intraperitoneal chemotherapy in the treatment of advanced ovarian cancer[J]. Chinese Journal of General Practice, 2024, 22(5): 768-771. doi: 10.16766/j.cnki.issn.1674-4152.003499
Citation: ZHANG Ying, YANG Bo, YIN Tian, ZHAO Yue, ZHANG Xinyi, LI Ying. Application of intermittent cytoreductive surgery + hyperthermic intraperitoneal chemotherapy in the treatment of advanced ovarian cancer[J]. Chinese Journal of General Practice, 2024, 22(5): 768-771. doi: 10.16766/j.cnki.issn.1674-4152.003499
shu

Application of intermittent cytoreductive surgery + hyperthermic intraperitoneal chemotherapy in the treatment of advanced ovarian cancer

doi: 10.16766/j.cnki.issn.1674-4152.003499
  • 1.

    Department of Gynaecologic Oncology, the First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui 233004, China

Funds:

 KJ2021A0727

  • Received Date: 2023-11-14
    Available Online: 2024-07-20
    Abstract
  •   Objective  To explore the efficacy and safety of intermittent cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced ovarian cancer.  Methods  Patients diagnosed with advanced ovarian cancer in the First Affiliated Hospital of Bengbu Medical University from November 2020 to September 2021 were selected. According to whether to use HIPEC, the patients were divided into an experimental group and a control group, with 45 cases in each group. The short-term outcomes and incidence of adverse effects after surgery and chemotherapy in two groups of patients were compared.  Results  The objective response rate (ORR) was 86.7% in the experimental group and 68.9% in the control group (P=0.043). The 2-year survival rate was 86.7% in the experimental group and 64.4% in the control group (P=0.014). The average progression-free survival (PFS) of the experimental group was (29.03±1.07) months, which was significantly higher than the control group [(16.60±1.12) months, P<0.001]. The adverse reactions after chemotherapy in the two groups were statistically significant in nausea/vomiting (P<0.05), and liver function injury (P<0.05). The incidences of abdominal distension and hypoproteinemia were 57.8% and 37.8% in the experimental group, and 2.2% and 2.2% in the control group, respectively (P<0.05). Conclusion The use of intermittent cytoreductive surgery combined with HIPEC is expected to improve the short-term treatment effect of patients with advanced ovarian cancer within a controlled range and ensure the safety of treatment.

     

    • FullText(HTML)
  • loading
    • References(16)
  • [1]
    南云泽, 李萌萌, 王彤, 等. 新辅助化疗联合间歇型肿瘤细胞减灭术治疗34例晚期卵巢癌的疗效及预后分析[J]. 延边大学医学学报, 2021, 44(1): 52-55. https://www.cnki.com.cn/Article/CJFDTOTAL-YBYB202101015.htm

    NAN Y Z, LI M M, WANG T et al. Efficacy and prognostic analysis of neoadjuvant chemotherapy combined with intermittent cytoreductive surgery in the treatment of 34 cases of advanced ovarian cancer[J]. Medical Journal of Yanbian University, 2021, 44(1): 52-55. https://www.cnki.com.cn/Article/CJFDTOTAL-YBYB202101015.htm
    [2]
    COLERIDGE S L, BRYANT A, KEHOE S, et al. Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer[J]. Cochrane Database Syst Rev, 2021, 7(7): CD005343. DOI: 10.1002/14651858.CD005343.
    [3]
    LHEUREUX S, BRAUNSTEIN M, OZA A M. Epithelial ovarian cancer: evolution of management in the era of precision medicine[J]. CA Cancer J Clin, 2019, 69(4): 280-304. doi: 10.3322/caac.21559
    [4]
    CHO J H, KIM S, SONG Y S. Neoadjuvant chemotherapy in advanced ovarian cancer: optimal patient selection and response evaluation[J]. Chin Clin Oncol, 2018, 7(6): 58. DOI: 10.21037/cco.2018.10.11.
    [5]
    SPRATT J S, ADCOCK R A, MUSKOVIN M, et al. Clinical delivery system for intraperitoneal hyperthermic chemotherapy[J]. Cancer Res, 1980, 40(2): 256-260.
    [6]
    中国抗癌协会妇科肿瘤专业委员会. 卵巢恶性肿瘤诊断与治疗指南(2021年版)[J]. 中国癌症杂志, 2021, 31(6): 490-500. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGAZ202106007.htm

    Gynecological Oncology Committee of Chinese anti-Cancer Association. Guidelines for the diagnosis and treatment of ovarian malignant tumors (2021 edition)[J]. Chinese Journal of Cancer, 2021, 31(6): 490-500. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGAZ202106007.htm
    [7]
    朱秀红, 毛翠玉, 张燕, 等. 卵巢癌新辅助化疗的研究进展[J]. 现代妇产科进展, 2023, 32(11): 865-869. https://www.cnki.com.cn/Article/CJFDTOTAL-XDFC202311016.htm

    ZHU X H, MAO C Y, ZHANG Y, et al. Research progress of neoadjuvant chemotherapy for ovarian cancer[J]. Progress of Modern Obstetrics and Gynecology, 2023, 32(11): 865-869. https://www.cnki.com.cn/Article/CJFDTOTAL-XDFC202311016.htm
    [8]
    中国抗癌协会宫颈癌专业委员会, 李晶, 林仲秋. 妇科肿瘤腹腔热灌注治疗临床应用指南(2023年版)[J]. 中国实用妇科与产科杂志, 2023, 39(9): 926-934. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGSF202309016.htm

    Cervical Cancer Committee of China Anti-Cancer Association, LI J, LIN Z Q. Group of Chinese Association of Obstetricians and Gynecologists Expert consensus on application of clinical medicines for hyperthermic intraperitoneal chemotherapy in the treatment of gynecological tumors (2024 edition)[J]. Chinese Journal of Applied Gynecology & Obstetrics, 2023, 39(9): 926-934. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGSF202309016.htm
    [9]
    LIM P Q, HAN I H, SEOW K M, et al. Hyperthermic intraperitoneal chemotherapy (HIPEC): an overview of the molecular and cellular mechanisms of actions and effects on epithelial ovarian cancers[J]. Int J Mol Sci, 2022, 23(17): 10078. DOI: 10.3390/ijms231710078.
    [10]
    WHITE M G, BADGWELL B. Oncologic components of HIPEC: key question: in patients with gastric or colorectal adenocarcinoma metastatic to the peritoneum, does cytoreductive surgery (CRS) plus hyperthermic intraperitoneal perfusion with chemotherapy (HIPEC) prolong survival or increase the risk of complications relative to CRS alone?[J]. Ann Surg Oncol, 2022, 29(11): 6561-6564. doi: 10.1245/s10434-021-11253-x
    [11]
    宋敏. CRS联合顺铂腹腔热灌注化疗治疗卵巢癌的近远期效果观察[J]. 当代医学, 2020, 26(19): 114-116. doi: 10.3969/j.issn.1009-4393.2020.19.046

    SONG M. Observation of short-term and long-term effect of CRS combined with cisplatin intraperitoneal hyperthermic perfusion chemotherapy in the treatment of ovarian cancer[J]. Contemporary Medicine, 2020, 26(19): 114-116. doi: 10.3969/j.issn.1009-4393.2020.19.046
    [12]
    李会俭, 项达军, 赵敏. 高精度持续循环腹腔热灌注化疗联合静脉化疗与常规静脉化疗治疗卵巢癌的疗效对比分析[J]. 贵州医药, 2017, 41(11): 1168-1170. doi: 10.3969/j.issn.1000-744X.2017.11.020

    LI H J, XISNG D J, ZHAO M. Comparison of the efficacy of high-precision continuous cyclic hyperthermic intraperitoneal chemotherapy combined with intravenous chemotherapy and conventional intravenous chemotherapy in the treatment of ovarian cancer[J]. Guizhou Medical Journal, 2017, 41(11): 1168-1170. doi: 10.3969/j.issn.1000-744X.2017.11.020
    [13]
    褚永姣, 任婷婷. 腹腔热灌注化疗联合肿瘤细胞减灭术对卵巢癌患者的治疗效果[J]. 癌症进展, 2023, 21(9): 966-969. https://www.cnki.com.cn/Article/CJFDTOTAL-AZJZ202309009.htm

    CHU Y J, REN T T. Effect of hyperthermic intraperitoneal chemotherapy combined with cytoreductive surgery on patients with ovarian cancer[J]. Cancer Progression, 2023, 21(9): 966-969. https://www.cnki.com.cn/Article/CJFDTOTAL-AZJZ202309009.htm
    [14]
    郭钰, 徐鹏, 王蓓蒂, 等. 血清肿瘤标志物在卵巢癌诊断中的研究进展[J]. 中华全科医学, 2021, 19(8): 1362-1366. doi: 10.16766/j.cnki.issn.1674-4152.002061

    GUO Y, XU P, WANG B D, et al. Research progress of serum tumor markers in the diagnosis of ovarian cancer[J]. Chinese Journal of General Practice, 2021, 19(8): 1362-1366. doi: 10.16766/j.cnki.issn.1674-4152.002061
    [15]
    DRAPKIN R, VON HORSTEN H H, LIN Y, et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas[J]. Cancer Res, 2005, 65(6): 2162-2169. doi: 10.1158/0008-5472.CAN-04-3924
    [16]
    VAN DRIEL W J, KOOLE S N, SZKORSKA K, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer[J]. N Engi J Med, 2018, 378(3): 230-240. doi: 10.1056/NEJMoa1708618
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(5)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (42) PDF downloads(2) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return